A rise in new treatments is on the horizon.
The demand in key markets (US, France, Germany, Italy, Spain, the UK, Japan) for drugs that treat ovarian cancer will increase from $1.2 billion in 2015 to over $5.2 billion by 2025, according to market research firm GlobalData.
New standard of care maintenance therapies for both newly diagnosed and recurrent patients, including first and second lines of treatment, will drive this growth. In particular, longer treatment regimes for poly ADP-ribose polymerase (PARP) inhibitors and immune checkpoint modulators with improved efficacy will be important.
Current competitors in the US market include AstraZeneca with Lynparza (olaparib) and Clovis Oncology with Rubraca (rucaparib). Many other PARP inhibitors are under development and showing promise in the clinic. However, questions still remain regarding which treatment stage(s) these drugs are best used. Drug developers that can address this issue while providing highly safe and efficacious therapies will be best positioned for success in what looks to be a crowded market.
